Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 279

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Open access
Lehmann, Brian D., Colaprico, Antonio, Silva, Tiago C., Chen, Jianjiao, An, Hanbing, Ban, Yuguang, Huang, Hanchen, Wang, Lily, James, Jamaal L., Balko, Justin M., Gonzalez-Ericsson, Paula I., Sanders, Melinda E., Zhang, Bing, Pietenpol, Jennifer A., Chen, X. Steven·2021·Nature Communications

Abstract

Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs subtypes include two basal-like (BL1, BL2), a mesenchymal (M) and a luminal androgen receptor (LAR) subtype. Through a comprehensive analysis of mutation, copy number, transcriptomic, epigenetic, proteomic, and phospho-proteomic patterns we describe the genomic landscape of TNBC subtypes. Mesenchymal subtype tumors display high mutation loads, genomic instability, absence of immune cells, low PD-L1 expression, decreased global DNA methylation, and transcriptional repression of antigen presentation genes. We demonstrate that major histocompatibility complex I (MHC-I) is transcriptionally suppressed by H3K27me3 modifications by the polycomb repressor complex 2 (PRC2). Pharmacological inhibition of PRC2 subunits EZH2 or EED restores MHC-I expression and enhances chemotherapy efficacy in murine tumor models, providing a rationale for using PRC2 inhibitors in PD-L1 negative mesenchymal tumors. Subtype-specific differences in immune cell composition and differential genetic/pharmacological vulnerabilities suggest additional treatment strategies for TNBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-26502-6

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 87 references

Cited by

See all 279

Metadata

Authors
Lehmann, B. D., Colaprico, A., Silva, T. C., Chen, J., An, H., Ban, Y., Huang, H., Wang, L., James, J. L., Balko, J. M., Gonzalez-Ericsson, P. I., Sanders, M. E., Zhang, B., Pietenpol, J. A., & Chen, X. S.
Venue
Nature Communications
Published
2021-11-01
Volume
12
Issue
1
Pages
6276-6276
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3208558332
Cited by
279
References
87
FWCI
12.70
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. https://app.cochat.ai/papers/10.1038/s41467-021-26502-6
The paper
Lehmann, B. D., Colaprico, A., Silva, T. C., Chen, J., An, H., Ban, Y., Huang, H., Wang, L., James, J. L., Balko, J. M., Gonzalez-Ericsson, P. I., Sanders, M. E., Zhang, B., Pietenpol, J. A., & Chen, X. S. (2021). Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nature Communications. https://doi.org/10.1038/s41467-021-26502-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.